Etanercept-synthesizing adipose-derived stem cell secretome:A promising therapeutic option for inflammatory bowel disease  

作　　者：Say-June Kim Ok-Hee Kim Ha-Eun Hong Ji Hyeon Ju Do Sang Lee 

机构地区：[1]Department of Surgery,Seoul St.Mary’s Hospital,College of Medicine,the Catholic University of Korea,Seoul 06591,South Korea [2]Catholic Central Laboratory of Surgery,Institute of Biomedical Industry,College of Medicine,the Catholic University of Korea,Seoul 06591,South Korea [3]Division of Rheumatology,Department of Internal Medicine,Seoul St.Mary’s Hospital,College of Medicine,The Catholic University of Korea,Seoul 06591,South Korea

出　　处：《World Journal of Gastrointestinal Surgery》2024年第3期882-892,共11页世界胃肠外科杂志（英文版）（电子版）

基　　金：Supported by the National Research Foundation of Korea(NRF)grant funded by the Korea government(MSIT),No.NRF-2021R1F1A1064566.

摘　　要：BACKGROUND Inflammatory bowel disease(IBD)is a chronic inflammatory condition of the gastrointestinal tract,with tumor necrosis factor(TNF)-αplaying a key role in its pathogenesis.Etanercept,a decoy receptor for TNF,is used to treat inflammatory conditions.The secretome derived from adipose-derived stem cells(ASCs)has anti-inflammatory effects,making it a promising therapeutic option for IBD.AIM To investigate the anti-inflammatory effects of the secretome obtained from ASCs synthesizing etanercept on colon cells and in a dextran sulfate sodium(DSS)-induced IBD mouse model.METHODS ASCs were transfected with etanercept-encoding mini-circle plasmids to create etanercept-producing cells.The secretory material from these cells was then tested for anti-inflammatory effects both in vitro and in a DSS-induced IBD mouse model.RESULTS This study revealed promising results indicating that the group treated with the secretome derived from etanercept-synthesizing ASCs[Etanercept-Secretome(Et-Sec)group]had significantly lower expression levels of inflammatory mediators,such as interleukin-6,Monocyte Chemoattractant Protein-1,and TNF-α,when compared to the control secretome(Ct-Sec).Moreover,the Et-Sec group exhibited a marked therapeutic effect in terms of preserving the architecture of intestinal tissue compared to the Ct-Sec.CONCLUSION These results suggest that the secretome derived from ASCs that synthesize etanercept has potential as a therapeutic agent for the treatment of IBD,potentially enhancing treatment efficacy by merging the anti-inflam-matory qualities of the ASC secretome with etanercept's targeted approach to better address the multifaceted pathophysiology of IBD.

关 键 词：Adipose-derived stem cells ETANERCEPT Inflammatory bowel disease SECRETOME Tumor necrosis factor-α 

分 类 号：R726.5[医药卫生—儿科]